PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics
Link
https://www.nature.com/articles/s41392-022-01025-8.pdf
Reference7 articles.
1. Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
2. Kang, Y.-L. et al. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 20803–20813 (2020).
3. Ikonomov, O. C., Sbrissa, D. & Shisheva, A. Small molecule PIKfyve inhibitors as cancer therapeutics: translational promises and limitations. Toxicol. Appl. Pharmacol. 383, 114771 (2019).
4. Li, P. et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 32, 322–324 (2022).
5. Zhang, Y. et al. Virus-free and live-cell visualizing SARS-CoV-2 cell entry for studies of neutralizing antibodies and compound inhibitors. Small Methods 5, 2001031 (2021).
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors;European Journal of Medicinal Chemistry;2024-01
2. TMT proteomics analysis reveals the mechanism of bleomycin-induced pulmonary fibrosis and effects of Ginseng honeysuckle superfine powdered tea;Chinese Medicine;2023-05-24
3. Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective;Journal of Medicinal Chemistry;2023-03-01
4. Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases;Viruses;2023-02-19
5. Virtual high-throughput screening: Potential inhibitors targeting aminopeptidase N (CD13) and PIKfyve for SARS-CoV-2;Open Life Sciences;2023-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3